Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy

Basler, Michael; Gröttrup, Marcus

Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy

Dateien

Basler_2-cd638k2zvyds2.pdfGröße: 3.6 MBDownloads: 462

Datum

2020

Open Access-Veröffentlichung

Open Access Green

Sammlungen

Biologie

Publikationstyp

Zeitschriftenartikel

Publikationsstatus

Published

Erschienen in

Genes & Immunity. Springer Nature. 2020, 21(5), pp. 273-287. ISSN 1466-4879. eISSN 1476-5470. Available under: doi: 10.1038/s41435-020-00109-1

Zusammenfassung

The proteasome is a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells that controls numerous cellular processes through regulated protein degradation. Proteasome inhibitors have significantly improved the survival of multiple myeloma patients. However, clinically approved proteasome inhibitors have failed to show efficacy against solid tumors, neither alone nor in combination with other therapies. Targeting the immunoproteasome with selective inhibitors has been therapeutically effective in preclinical models for several autoimmune diseases and colon cancer. Moreover, immunoproteasome inhibitors prevented the chronic rejection of allogeneic organ transplants. In recent years, it has become apparent that inhibition of one single active center of the proteasome is insufficient to achieve therapeutic benefits. In this review we summarize the latest insights how targeting multiple catalytically active proteasome subunits can interfere with disease progression in autoimmunity, growth of solid tumors, and allograft rejection.

Fachgebiet (DDC)

570 Biowissenschaften, Biologie

Zitieren

ISO 690

BASLER, Michael, Marcus GRÖTTRUP, 2020. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. In: Genes & Immunity. Springer Nature. 2020, 21(5), pp. 273-287. ISSN 1466-4879. eISSN 1476-5470. Available under: doi: 10.1038/s41435-020-00109-1

BibTex

@article{Basler2020-11Recen-50694,
  year={2020},
  doi={10.1038/s41435-020-00109-1},
  title={Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy},
  number={5},
  volume={21},
  issn={1466-4879},
  journal={Genes & Immunity},
  pages={273--287},
  author={Basler, Michael and Gröttrup, Marcus}
}

RDF

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/50694">
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dcterms:available>
    <dc:language>eng</dc:language>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/50694"/>
    <dc:creator>Basler, Michael</dc:creator>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/50694/1/Basler_2-cd638k2zvyds2.pdf"/>
    <dcterms:abstract xml:lang="eng">The proteasome is a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells that controls numerous cellular processes through regulated protein degradation. Proteasome inhibitors have significantly improved the survival of multiple myeloma patients. However, clinically approved proteasome inhibitors have failed to show efficacy against solid tumors, neither alone nor in combination with other therapies. Targeting the immunoproteasome with selective inhibitors has been therapeutically effective in preclinical models for several autoimmune diseases and colon cancer. Moreover, immunoproteasome inhibitors prevented the chronic rejection of allogeneic organ transplants. In recent years, it has become apparent that inhibition of one single active center of the proteasome is insufficient to achieve therapeutic benefits. In this review we summarize the latest insights how targeting multiple catalytically active proteasome subunits can interfere with disease progression in autoimmunity, growth of solid tumors, and allograft rejection.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/50694/1/Basler_2-cd638k2zvyds2.pdf"/>
    <dcterms:title>Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy</dcterms:title>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dc:date>
    <dc:contributor>Basler, Michael</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:issued>2020-11</dcterms:issued>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
  </rdf:Description>
</rdf:RDF>

Universitätsbibliographie

Ja

Begutachtet

Ja